RE: Whats the company worth without Zenakine?20 Feb 2026 10:37
Well Zenakine was always the potential big earner as it was supported by a FTSE 100 company. However, payment is via a royalty payment model so payments will depend on how important the product is to Croda. I note the product info shows an improvement in 13% of users, which seems low to me, so not sure if this will fly off the shelves. A lot will depend on how Croda market this - if they are prepared to spend money on promoting the product (influencers etc) it may do well . The fact that it appears we've had no royalties in 2025 and 2026 numbers are being revised down appears to show the product roll out is going slowly.
As for Axisbiotix-Ps getting it into Superdrug is a great achievement. However, selling to retail is a drag as the product must be produced upfront and then not paid for for say 3 months. Then future sales are unknown but inventory needs to be ready as and when requested. I note it is a 2 year agreement so Superdrug could pull the plug after 24 months. Additionally, there will probably be an exclusivity so this won't be in Boots anytime soon.
The product is not cheap (£30) and although the marketing states "72% of participants reported that their skin felt better after taking the supplement for 28 days." i note that the advise is to take it for a minimum of 56 days so i suspect some of these improvements will be quite minor.
I remember Opti getting products into H&B and hoping this would be a game changer. It wasn't.
Ultimately SBTX is a loss making company and i fear will remain so without decent Zenakine royalties